KYKeertana Yalamanchili

Keertana Yalamanchili

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Keertana Yalamanchili has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher Stone

    Division of Cardiothoracic Surgery, Department of Surgery, Brown University, Providence, RI, USA 02912

    2 shared publications
  • Dwight D. Harris

    Division of Cardiothoracic Surgery, Department of Surgery, Brown University, Providence, RI, USA 02912

    2 shared publications
  • Meghamsh Kanuparthy

    Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Brown University

    2 shared publications
  • Christopher Stone

    Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA

    1 shared publication
  • Dwight D Harris

    Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA

    1 shared publication
  • Frank W Sellke

    Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA

    1 shared publication

Latest Publications

  • Open Access

    Metformin's effects beyond ischemia: Evaluating cardioprotection in nonischemic myocardium in a large animal model of coronary and metabolic disease

    by Keertana Yalamanchili, Christopher Stone, Kelsey C. Muir, Dwight D. Harris, Meghamsh Kanuparthy, Frank W. Sellke


  • Canagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces lung fibrosis in left heart dysfunction

    by Meghamsh Kanuparthy, Dwight D Harris, Mark Broadwin, Christopher Stone, Jad Hamze, Keertana Yalamanchili, Sharif Sabe, Frank W Sellke

    Background: Left heart failure is the most common cause of pulmonary hypertension and increases morbidity and mortality. We investigate the use of canagliflozin, an antidiabetic Sodium-glucose Cotransporter-2 Inhibitor, which is first-line therapy in congestive heart failure, on pulmonary fibrosis in a porcine model of chronic myocardial ischemia. Methodology: Sixteen Yorkshire swine, eight in a normal diet control arm (NDC) and eight in the canagliflozin arm (CAN), underwent left thoracotomy and ameroid constrictor placement on the left circumflex artery. Seven weeks after placement, the swine underwent harvest procedure. During harvest, left ventricular contractility was quantified by direct left ventricular pressure-volume loops. Protein expression was quantified by immunoblotting and Masson's trichrome staining was utilized to assess perivascular collagen deposition. Results: Analysis of left ventricular ejection fraction demonstrated no significant difference between CAN and NDC. Western blot analysis demonstrated increases in TGFβ signaling pathways with decreased free TGFβ and TGFβ monomers in CAN pigs ( p < 0.01). Downstream mediators of TGFβ were also increased in NDC with an increase in phospho-SMAD2/3 activity ( p = 0.005). Masson's Trichrome analysis of lung tissue demonstrated a trend toward reduced perivascular collagen deposition in CAN swine lungs ( p = 0.086). Conclusions: Canagliflozin ameliorates chronic fibrotic changes related to pulmonary hypertension in left ventricular failure. While there was a strong trend toward significance in histologic analysis, this may be limited by the duration of our model. Western blot analysis, however, demonstrates that CAN's modulation of TGFβ signaling pathways may play a role in the management of secondary pulmonary hypertension.

  • Open Access

    Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease

    by Christopher Stone, Dwight D. Harris, Mark Broadwin, Meghamsh Kanuparthy, Ju-Woo Nho, Keertana Yalamanchili, Jad Hamze, M. Ruhul Abid, Frank W. Sellke

    BACKGROUND: Coronary artery disease is the leading cause of death worldwide. It imposes an enormous symptomatic burden on patients, leaving many with residual disease despite optimal procedural therapy and up to one-thirds with debilitating angina amenable neither to procedures, nor to current pharmacological options. Semaglutide (SEM), a GLP-1 (glucagon-like peptide 1) agonist originally approved for management of diabetes, has garnered substantial attention for its capacity to attenuate cardiovascular risk. Although subgroup analyses in patients indicate promise, studies explicitly designed to isolate the impact of SEM on the sequelae of coronary artery disease, independently of comorbid diabetes or obesity, are lacking. METHODS: Yorkshire swine (n=17) underwent placement of an ameroid constrictor around the left circumflex coronary artery to induce coronary artery disease. Oral SEM was initiated postoperatively at 1.5 mg and scaled up in 2 weeks to 3 mg in treatment animals (n=8) for a total of 5 weeks, while control animals (n=9) received no drug. All then underwent myocardial harvest with acquisition of perfusion and functional data using microsphere injection and pressure-volume loop catheterization. Immunoblotting, immunohistochemistry, and immunofluorescence were performed on the most ischemic myocardial segments for mechanistic elucidation. RESULTS: SEM animals exhibited improved left ventricular ejection fraction, both at rest and during rapid myocardial pacing (both P P P P =0.008). These changes were associated with increased activation of the endothelial-protective AMPK (AMP-activated protein kinase) pathway ( P =0.005), coupled with downstream increases in eNOS (endothelial NO synthase; P =0.014). CONCLUSIONS: This study reveals the capacity of oral SEM to augment cardiac function in the chronically ischemic heart in a highly translational large animal model, likely through AMPK-mediated improvement in endothelial function and perfusion to the ischemic myocardium.